These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 31633798)

  • 21. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
    Nie RC; Chen FP; Yuan SQ; Luo YS; Chen S; Chen YM; Chen XJ; Chen YB; Li YF; Zhou ZW
    Eur J Cancer; 2019 Jan; 106():1-11. PubMed ID: 30453169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials.
    Zhao Q; Xie R; Lin S; You X; Weng X
    Biomed Res Int; 2018; 2018():3820956. PubMed ID: 30345301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
    Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y
    Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
    Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis.
    Landre T; Des Guetz G; Chouahnia K; Fossey-Diaz V; Culine S
    Drugs Aging; 2020 Oct; 37(10):747-754. PubMed ID: 32681403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis.
    Mo J; Hu X; Gu L; Chen B; Khadaroo PA; Shen Z; Dong L; Lv Y; Chitumba MN; Liu J
    World J Surg Oncol; 2020 Jan; 18(1):15. PubMed ID: 31959178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.
    Conforti F; Pala L; Bagnardi V; Viale G; De Pas T; Pagan E; Pennacchioli E; Cocorocchio E; Ferrucci PF; De Marinis F; Gelber RD; Goldhirsch A
    J Natl Cancer Inst; 2019 Aug; 111(8):772-781. PubMed ID: 31106827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis.
    Ninomiya K; Oze I; Kato Y; Kubo T; Ichihara E; Rai K; Ohashi K; Kozuki T; Tabata M; Maeda Y; Kiura K; Hotta K
    Acta Oncol; 2020 Mar; 59(3):249-256. PubMed ID: 31782328
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.
    Schulz C; Gandara D; Berardo CG; Rosenthal R; Foo J; Morel C; Ballinger M; Watkins C; Chu P
    Clin Lung Cancer; 2019 Nov; 20(6):451-460.e5. PubMed ID: 31375454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
    Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
    Li J; Gu J
    Future Oncol; 2019 May; 15(14):1667-1678. PubMed ID: 31041879
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis.
    Mulkey F; Theoret MR; Keegan P; Pazdur R; Sridhara R
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32107275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
    Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
    JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
    Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
    Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma.
    Lee J; Choi Y; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
    Eur J Cancer; 2020 Jun; 132():150-158. PubMed ID: 32371248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
    Botticelli A; Cirillo A; Strigari L; Valentini F; Cerbelli B; Scagnoli S; Cerbelli E; Zizzari IG; Rocca CD; D'Amati G; Polimeni A; Nuti M; Merlano MC; Mezi S; Marchetti P
    Front Immunol; 2021; 12():705096. PubMed ID: 34434192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.